387 results on '"Gheorghe, Liana"'
Search Results
2. Nonalcoholic Fatty Liver Disease Within Other Causes of Chronic Liver Diseases
3. A global research priority agenda to advance public health responses to fatty liver disease
4. EASL Clinical Practice Guidelines on hepatitis delta virus
5. Indications for Liver Transplantation in Adults: Selection of Patients with End Stage Liver Diseases
6. THU-186 Long term risk assessment of patients with primary sclerosing cholangitis using clinical prognosis models
7. Prospective study of hepatitis B and D epidemiology and risk factors in Romania: A 10-year update
8. Hepatitis B Prevalence and Referral Rates in Vulnerable Populations Undergoing Community-Based Screening—Results from the LIVE(RO)2 Program.
9. Sylimarin Versus Essential Phospholipids in Metabolic Associated Steatotic Liver Disease (MASLD) – A Prospective Comparative Randomized Trial
10. Intravenous versus subcutaneous delivery of biotherapeutics in IBD: an expert’s and patient’s perspective
11. A portrait of viral hepatitis in the Roma population highlighting potential disparities
12. A New Dawn in Hepatitis D Management.
13. Metabolic-associated fatty liver disease in socio-economic vulnerable population with chronic hepatitis B and C
14. Week 48 results of the phase 3 D-LIVR study, a randomized double-blind, placebo-controlled trial evaluating the safety and efficacy of Lonafarnib-boosted with Ritonavir with or without Peginterferon Alfa in patients with chronic hepatitis delta
15. Pre and post-liver transplant outcome of cirrhotic patients with acute on chronic liver failure
16. Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study
17. Fatigue Is Associated with Anxiety and Lower Health-Related Quality of Life in Patients with Inflammatory Bowel Disease in Remission
18. Real World Efficacy and Safety of Sofosbuvir + Velpatasvir + Voxilaprevir in Romanian Patients with Genotype 1b HCV Infection Non-reponders to DAAs Therapy
19. Host and immunosuppression-related factors influencing fibrosis occurrence post liver transplantation
20. Predictive Factors for Death on a Long Waiting List for Liver Transplantation after an Episode of Acute on Chronic Liver Failure
21. Efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with ribavirin for the treatment of HCV genotype 1b compensated cirrhosis in patients aged 70 years or older
22. The risks of hepatocellular carcinoma and variceal bleeding after HCV eradication with direct-acting antiviral therapy: a propensity score analysis
23. Atypical Immunohistochemistry Features in an AFP-producing Colon Cancer
24. Editorial: Sarcopenia, Frailty and Nutrition in Liver Diseases
25. An international survey on patterns of practice in NAFLD and expectations for therapies—The POP‐NEXT project
26. The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?
27. Do the needle type and the operator experience influence liver biopsy specimen quality?
28. The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?
29. Mutation analysis of the ATP7B gene in a new group of Wilson's disease patients: Contribution to diagnosis
30. Health-Related Quality of Life in Patients with Inflammatory Bowel Disease in Clinical Remission: What Should We Look For?
31. Assessment of Sarcopenia Related Quality of Life Using SarQoL® Questionnaire in Patients With Liver Cirrhosis
32. The Predictive Role of Variceal Band Ligation in the Development of Portal Vein Thrombosis in Cirrhotic Patients
33. Genetic and Life Style Risk Factors for Recurrent Non-alcoholic Fatty Liver Disease Following Liver Transplantation
34. Reply to “Anticoagulant treatment in cirrhotic portal vein thrombosis –how wide can we open the window?”
35. Diagnostic Delay in Romanian Patients with Inflammatory Bowel Disease: Risk Factors and Impact on the Disease Course and Need for Surgery
36. Anticoagulation Therapy for Portal Vein Thrombosis in Patients with Cirrhosis in a Tertiary Center Experience
37. Risk Factors for Extraintestinal Manifestations in Inflammatory Bowel Diseases - Data from the Romanian National Registry
38. Advancing the global public health agenda for NAFLD: a consensus statement
39. Long Term Follow-up of Liver Transplant Recipients: Considerations for Non-transplant Specialists
40. GAVE: a gastroenterologist challenge
41. Normal histology, the new target for ulcerative colitis treatment, might not be the cure
42. The impact of direct acting antivirals on hepatitis C virus disease burden and associated costs in four european countries
43. Impact of Sustained Virological Response on Metabolic Profile and Kidney Function in Cured HCV Liver Transplant Recipients
44. COVID-19 in Liver Transplant Candidates: Pre- and Post-Transplant Outcome
45. A Combined Program of Cadaveric and Living-Related Liver Transplantation in a Single Center: An Experience of 1,000 Operations
46. FRI-150 - Metabolic-associated fatty liver disease in socio-economic vulnerable population with chronic hepatitis B and C
47. GS-012 - Week 48 results of the phase 3 D-LIVR study, a randomized double-blind, placebo-controlled trial evaluating the safety and efficacy of Lonafarnib-boosted with Ritonavir with or without Peginterferon Alfa in patients with chronic hepatitis delta
48. Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe
49. The Prevalence of HCV Infection and Risk Factors in a Hospital- Based Population Screening, a First Step to the Micro-Elimination of HCV Infection in Medical Institutions from Romania - Results of the HepC ALERT Study
50. Clinical and economic consequences of antiviral treatment for hepatitis C chronic infection in Europe: analysis of England, Italy, Romania and Spain data
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.